To compare drug survival rates among different biologics for psoriasis in bionaive and bioexperienced patients, emphasizing the impact of prior biologic exposure.
Key Findings:
Ustekinumab showed higher drug survival than adalimumab or secukinumab in bionaive patients.
In bioexperienced patients, bimekizumab, guselkumab, and risankizumab had the highest 2-year drug survival rates.
At 5 years, the risk of treatment discontinuation was lowest for ustekinumab (37%) compared to adalimumab (51%) and secukinumab (54%).
Bimekizumab (27%), guselkumab (29%), and risankizumab (25%) had lower discontinuation rates than ustekinumab in bioexperienced patients.
Interpretation:
The study highlights significant differences in treatment persistence among various biologics, which may influence clinical decision-making.
Limitations:
The study is based on registry data, which may have inherent biases, including selection bias and reporting inconsistencies.
Findings may not be generalizable to populations outside Denmark due to demographic differences.
Conclusion:
The results may guide therapy selection in routine clinical practice, emphasizing the importance of biologic choice based on patient history and prior treatment responses.
